NCT07044414Completed
Effectiveness of Manual Acupuncture for Head and Neck Cancer Patients Undergoing Chemoradiation
Effectiveness of Manual Acupuncture as an Adjuvant Therapy for Head and Neck Cancer Patients Undergoing Chemoradiation at the Radiation Oncology Polyclinic of RSUPN DR. Cipto Mangunkusumo
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
The goal of this clinical trial is to assess whether manual acupuncture (MA) is more effective than sham acupuncture in improving leukocyte count and reducing cancer-related fatigue (CRF) in head and neck cancer (HNC) patients undergoing chemoradiation therapy (CRT). The main questions it aims to answer are: * Does MA, compared to sham acupuncture, increase leukocyte and absolute neutrophil count (ANC) during CRT? * Does MA, compared to sham acupuncture, reduce the severity of CRF as measured by the Visual Analogue Scale-Fatigue (VAS-F)? * Does MA, compared to sham acupuncture, improve quality of life as measured by the EORTC QLQ-C30 questionnaire? Participants will: * Be adult patients with head and neck cancer who have completed induction chemotherapy and are undergoing CRT * Be screened based on inclusion and exclusion criteria, including normal INR and platelet count above 25,000/mm³ * Be randomly assigned to either the MA group or sham group using Park sham needle * Receive acupuncture at points ST36, SP6, CV4, and CV6 three times per week for seven sessions (total 21 sessions) * Be evaluated for leukocyte count, ANC, fatigue (VAS-F), and quality of life (EORTC QLQ-C30) at baseline and at weekly intervals during therapy
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 34 (actual)
- First submitted
- 23 Jun 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 12 Dec 2025
- Lead sponsor
- Universitas Indonesia
- Diseases
- Head and neck cancer
- NCT number
- NCT07044414
What you commit to
- Study type: Interventional
- Participants enrolled: 34
- From 1 Sept 2025 to the primary completion date, 12 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with severe comorbidities such as chronic kidney failure, metastatic liver cirrhosis, or heart disease.
Lab values
- Subjects currently undergoing other therapies that may affect leukocyte counts, such as immunomodulatory therapy or high-dose corticosteroid use.
- Subjects with blood clotting disorders or those currently taking anticoagulants, confirmed by laboratory results: neutrophils \<1,000/mm³, platelets \<25,000/mm³, INR \>2.0, or partial thromboplastin time \>20 seconds.
Other
- Subjects who are still smoking or consuming alcohol.
- Pregnant or breastfeeding women.
Who the study is looking for
- Subjects diagnosed with head and neck cancer (HNC) based on histopathological examination, who have completed induction chemotherapy and are scheduled to undergo radiotherapy.
- Subjects aged ≥18 years.
- Subjects willing to participate in this study and provide written informed consent.
- Subjects with a Mini Mental State Examination (MMSE) score ≥24.
- Subjects with oxygen saturation ≥95% on room air.
- Subjects with stage III or IVA cancer.
- Subjects receiving a radiation dose of 66-70 Gy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitas Indonesia Coordinator of this site? Confirm its status | Jakarta Pusat | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.